The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer

Emily Golden, Rabab Rashwan, Eleanor A. Woodward, Agustin Sgro, Edina Wang, Anabel Sorolla, Charlene Waryah, Wan Jun Tie, Elisabet Cuyàs, Iwona Kardaś, Piotr Kozlowski, Elizabeth K.M. Johnstone, Heng B. See, Ciara Duffy, Jeremy Parry, Kim A. Lagerborg, Piotr Czapiewski, Javier A. Menendez, Adam Gorczyński, Bartosz WasagKevin D.G. Pfleger, Christina Curtis, Bum Kyu Lee, Jonghwan Kim, Joseph Cursons, Nathan J. Pavlos, Wojciech Biernat, Mohit Jain, Andrew J. Woo, Andrew Redfern, Pilar Blancafort

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Adipogenesis associated Mth938 domain containing (AAMDC) represents an uncharacterized oncogene amplified in aggressive estrogen receptor-positive breast cancers. We uncover that AAMDC regulates the expression of several metabolic enzymes involved in the one-carbon folate and methionine cycles, and lipid metabolism. We show that AAMDC controls PI3K-AKT-mTOR signaling, regulating the translation of ATF4 and MYC and modulating the transcriptional activity of AAMDC-dependent promoters. High AAMDC expression is associated with sensitization to dactolisib and everolimus, and these PI3K-mTOR inhibitors exhibit synergistic interactions with anti-estrogens in IntClust2 models. Ectopic AAMDC expression is sufficient to activate AKT signaling, resulting in estrogen-independent tumor growth. Thus, AAMDC-overexpressing tumors may be sensitive to PI3K-mTORC1 blockers in combination with anti-estrogens. Lastly, we provide evidence that AAMDC can interact with the RabGTPase-activating protein RabGAP1L, and that AAMDC, RabGAP1L, and Rab7a colocalize in endolysosomes. The discovery of the RabGAP1L-AAMDC assembly platform provides insights for the design of selective blockers to target malignancies having the AAMDC amplification.

Original languageEnglish
Article number1920
JournalNature Communications
Issue number1
Publication statusPublished - 1 Dec 2021


Dive into the research topics of 'The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer'. Together they form a unique fingerprint.

Cite this